other material
confidence high
sentiment positive
materiality 0.75
Azenosertib shows RB1 loss sensitivity in SCLC/TNBC; cfDNA MR predicts HGSOC response
Zentalis Pharmaceuticals, Inc.
- Preclinical: RB1 loss sensitizes TP53-mutant SCLC/TNBC cells; in vivo TGI 90% in RB1-mutant vs 49% in WT xenografts (Ex-99.1).
- Clinical (N=123 HGSOC): cfDNA TP53 molecular response (MR) predicts RECIST response; MR+ median TTP 5.49 vs 2.69 months for MR- (HR 0.43, p<0.0001).
- Complete MR (mCR) yields 6.5-month median TTP; MR precedes RECIST by 14 weeks for responders and 8 weeks for progressors (Ex-99.2).
- Azenosertib shows synergistic activity with encorafenib + cetuximab in BRAF V600E preclinical models (Ex-99.4).